Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Buys $94,500.00 in Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Lonnel Coats purchased 90,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average price of $1.05 per share, for a total transaction of $94,500.00. Following the completion of the purchase, the chief executive officer now directly owns 914,359 shares of the company’s stock, valued at $960,076.95. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Lonnel Coats also recently made the following trade(s):

• On Friday, November 10th, Lonnel Coats purchased 10,000 shares of Lexicon Pharmaceuticals stock. The shares were purchased at an average price of $1.01 per share, for a total transaction of $10,100.00.

Lexicon Pharmaceuticals Stock Up 5.7 %

Lexicon Pharmaceuticals stock opened at $1.12 on Monday. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.92 and a twelve month high of $3.79. The stock’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.91. The company has a current ratio of 6.92, a quick ratio of 6.91 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $274.32 million, a P/E ratio of -1.47 and a beta of 1.16.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Lexicon Pharmaceuticals had a negative return on equity of 118.90% and a negative net margin of 29,728.25%. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.49 million. As a group, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Citigroup decreased their price target on Lexicon Pharmaceuticals from $8.00 to $5.00 in a research note on Friday, August 4th.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Artal Group S.A. lifted its holdings in Lexicon Pharmaceuticals by 30.9% during the 2nd quarter. Artal Group S.A. now owns 117,553,284 shares of the biopharmaceutical company’s stock worth $269,197,000 after buying an additional 27,775,050 shares during the last quarter. BVF Inc. IL boosted its holdings in Lexicon Pharmaceuticals by 23.8% in the second quarter. BVF Inc. IL now owns 19,995,332 shares of the biopharmaceutical company’s stock valued at $45,789,000 after purchasing an additional 3,846,153 shares in the last quarter. BlackRock Inc. raised its holdings in Lexicon Pharmaceuticals by 12.8% during the second quarter. BlackRock Inc. now owns 6,379,186 shares of the biopharmaceutical company’s stock worth $14,608,000 after purchasing an additional 722,259 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Lexicon Pharmaceuticals by 34.0% during the third quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company’s stock worth $12,614,000 after purchasing an additional 1,334,318 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Lexicon Pharmaceuticals by 0.9% in the first quarter. JPMorgan Chase & Co. now owns 3,305,991 shares of the biopharmaceutical company’s stock valued at $8,034,000 after buying an additional 29,193 shares during the last quarter.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.